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Epidermal growth factor (EGF) signalling is well known for its multifaceted functions in development and tissue homoeostasis. The
EGF family of ligands and receptors (ERBB family) have also been extensively investigated for their roles in promoting tumourigenesis
and metastasis in a variety of cancer types. Recent findings indicate that EGF signalling is an important mediator of bone metastasis in
breast, prostate and kidney cancers. The EGF signalling stimulates the growth of bone metastasis directly by increasing tumour cell
proliferation and indirectly by engaging bone stromal cell in metastasis-promoting activities. Therefore, molecular targeting of ERBB
receptors may benefit patients with bone metastasis and should be evaluated in clinical trials.
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Epidermal growth factor (EGF) signalling is initiated by the
binding of EGF family members to the extracellular domain of
erythroblastic leukemia viral oncogene homologue (ERBB) recep-
tors. The ERBB receptor tyrosine kinase family consists of four
members: epidermal growth factor receptor (EGFR)/ERBB1/HER1,
ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4 (Hynes and Lane,
2005; Normanno et al, 2006). Each member has distinct binding
affinities to different ligands that allows the classification of
ligands into three groups: in the first group, EGF, transforming
growth factor-a (TGF-a) and amphiregulin (AREG) specifically
bind to EGFR; in the second group, betacellulin, heparin-binding
EGF (HB-EGF) and epiregulin bind to both EGFR and ERBB4; the
third class include neuregulins (NRGs) that bind to either only
ERBB4 (NRG3 and NRG4) or both ERBB3 and ERBB4 (NRG1 and
NRG2). None of the EGF family ligands binds to ERBB2, because
ERBB2 ectodomain is locked in a conformation that block the
ligand-binding site. Despite lacking a cognate ligand, ERBB2 can
indirectly mediate signalling when forming heterodimers with a
ligand-bound ERBB receptor.
On binding, ERBBs form homo- or heterodimers and activate
multiple important pathways involving effectors such as rat
sarcoma viral oncogene homologue (RAS)/mitogen-activated
protein kinase, phosphatidylinositol 3-kinase-AKT, mammalian
target of rapamycin, signal transducer and activator of transcrip-
tion, SRC tyrosine kinase, phospholipase C-g1/protein kinase C
(PKC) and p27 (Hynes and Lane, 2005; Wieduwilt and Moasser,
2008). The activation of these pathways has essential functions in
many aspects of development and tissue homoeostasis. Aberrant
activation of ERBBs in ligand-dependent and -independent ways in
epithelial tumours promotes tumour cell proliferation, survival,
migration and metastasis (Jorissen et al, 2003; Hynes and Lane,
2005). Recently, the role of EGF signalling in mediating tumour–
stroma interaction in the tumour microenvironment becomes
increasingly recognised (De Luca et al, 2008). In this review, we
will first briefly overview the regulation and functions of EGF
signalling pathway in mammalian development and tumourigen-
esis. Next, we will introduce the molecular mechanisms governing
bone homoeostasis and bone metastasis. Finally, we will discuss
several recent findings that established a role for EGF signalling in
the complex network of tumour–stromal cross talks during the
formation of osteolytic bone metastasis (Kim et al, 2003; Weber
et al, 2003; Normanno et al, 2005; Lu et al, 2009). These studies
provide the foundation for evaluating ERBBs and their ligands as
potential therapeutic targets for controlling bone metastasis.
THE REGULATION AND FUNCTION OF EGF
SIGNALLING IN DEVELOPMENT
The activity of the EGF signalling pathway is controlled at several
levels. Under physiological conditions, the ERBB receptor activity
is largely dependent on ligand availability, which is in part
controlled post-translationally through a process called ecto-
domain shedding (Hynes and Lane, 2005; Wieduwilt and Moasser,
2008; Schneider and Wolf, 2009). The extracellular domain of
EGF family ligands is cleaved by proteases belonging to families
of matrix metalloproteinase (MMP), a disintegrin and metallo-
protease (ADAM), and a disintegrin-like and metalloprotease with
thrombospondin (ADAMTS). Ectodomain shedding occurs in
response to diverse stimuli and most often after activation of
G-protein-coupled receptors by ligands such as endothelin-1,
bombesin, thrombin, lysophosphatidic acid and angiotensin-II
(Wieduwilt and Moasser, 2008). Soluble EGF-like ligands can
activate ERBBs on the same cell (autocrine), adjacent cells
(paracrine) or cells in other organs (endocrine). The importance
of ectodomain shedding in regulating ERBB activity is shown
by the phenotypes from mice with endogenous HB-EGF replaced
with either an uncleavable form or a constitutively soluble form of
HB-EGF (Yamazaki et al, 2003). The former leads to severe heart
failure and enlarged heart valves (similar to the phenotypes in
HB-EGF-null and EGFR-null animals), whereas the latter causes
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www.bjcancer.comhyperplasia in the skin and heart. Our recent study highlights the
importance of ectodomain shedding of HB-EGF, AREG and TGF-a
by proteases MMP1 and ADAMTS1 in the establishment of
paracrine signalling cascade in bone metastasis (discussed below)
(Lu et al, 2009). Besides the G-protein-coupled receptors, other
signals can also activate protease-mediated ectodomain shedding,
such as Wnt/Frizzled and oestradiol/oestrogen receptor (Hynes
and Lane, 2005). Signal attenuation of EGF signalling is achieved
through tyrosine dephosphorylation, receptor endocytosis and
regulation of receptor dimerisation (Wieduwilt and Moasser,
2008). Systems biology studies reveal that the robustness and
dynamic control of the EGF signalling is achieved by positive
feedback loop (heterodimerisation with ERBB2, autocrine and
paracrine), negative feedback loop (signal attenuation) and
buffering (regulation of heterodimer formation and stability of
ERBB2 by HSP90) (Citri and Yarden, 2006). Unfortunately,
systems control in the signalling pathway can be overridden by
pathological conditions, such as cancer, causing hyperactive
signalling activity and uncontrolled cell proliferation.
The functions of ERBBs and EGF family ligands during
mammalian development are studied by the gene targeting technique
in mice. Deficiency in any of the four ERBBs leads to embryonic or
perinatal death (Wieduwilt and Moasser, 2008). Phenotypic analyses
of the knockout mice indicate that each ERBB receptor has
indispensable roles in development and that functional redundancy
among the receptors, if any, is minimal. In contrast, mice lacking
genes encoding the EGF family ligands, including AREG, betacellulin,
EGF, epiregulin and TGF-a, are viable and show much less severe
phenotypes, indicating high level of redundancy. However, defi-
ciency of the two EGF-like ligands, NRG1 and HB-EGF, does cause
lethality, suggesting that in spite of the functional redundancy of EGF
signalling in the development of some tissues, restricted ligand–
receptor pairing is required for certain defined organs (Citri and
Yarden, 2006; Wieduwilt and Moasser, 2008).
EGF SIGNALLING IN CANCER AND TARGETED
THERAPEUTICS
The ERBB receptors and ligands are frequently overexpressed by
carcinoma cells (Normanno et al, 2006). The EGFR and ERBB3 are
overexpressed in 50–70% of lung, colon and breast carcinoma;
ERBB2 is overexpressed in 30% of breast cancer patients; ERBB4 is
expressed in 50% of breast cancer patients and 22% of colon
cancer patients. Mutations of ERBB genes in cancer have been
intensely investigated and found in all four members (Normanno
et al, 2006; Wieduwilt and Moasser, 2008). For example, gene
amplification and extracellular domain deletions of EGFR are
found in 40–60% of glioblastoma multiforme patients. Kinase
domain mutations of EGFR are found in 30–50% East Asian and
5–10% non-East Asian patients of non-small cell lung cancer.
Gene amplification of ERBB2 is found in 20–30% of breast cancer
patients. Gene amplification leads to gene overexpression, whereas
extracelluar domain truncation and kinase domain mutations
often render the receptors constitutively active. The ERBB2
amplification and overexpression in node-positive breast cancer
patients are associated with poor prognosis independent of other
markers (Ravdin and Chamness, 1995). Co-expression of two or
more members of ERBB family is associated with a worse outcome
(Normanno et al, 2006). Although mutation of EGF family ligands
was not documented, the ligands are frequently expressed, and
often co-expressed in breast, colon, lung, ovarian, gastric and
prostate carcinomas (Normanno et al, 2006; De Luca et al, 2008).
These results raise the possibility of constitutive activation of
ERBB signalling by an autocrine loop.
The transforming activity of ERBB receptors and ligands are
best demonstrated in mice with overexpression of these genes in
the mouse mammary tissue. The EGFR overexpression leads to
hyperplasia in virgins and dysplasia and tubular adenocarcinoma
in lactating mice (Brandt et al, 2000). Overexpression of wild-type
murine homologue of ERBB2 (neu) or activated neu leads to focal
adenocarcinoma after long latency (Guy et al, 1992) or multifocal
adenocarcinoma with a shorter latency (Muller et al, 1988),
respectively. Transgenic overexpression of TGF-a causes a range of
mammary abnormalities, including lobular hyperplasia, cystic
hyperplasia, adenoma and adenocarcinoma (Matsui et al, 1990). In
addition to stimulating tumour cell proliferation, EGF signalling
has also been implicated in modulating functions of stromal cells
in the tumour microenvironment, such as tumour-associated
angiogenesis and bone metastasis (De Luca et al, 2008). Epidermal
growth factor stimulates vascular endothelial growth factor
expression in a panel of EGFR-positive cancer cells, including
glioblastoma, gastric cancer, vulvar squamous carcinoma, bladder
cancer and prostate cancer. The EGF family ligands can also exert
direct mitogenic effects on tumour-associated endothelial cells
(De Luca et al, 2008).
The EGF signalling network provides an array of therapeutic
targets for the control of tumour growth. Most efforts have been
focused on ERBB2 and EGFR. Currently, ERBB-targeted thera-
peutics in clinical use includes trastuzumab for metastatic breast
cancer overexpressing ERBB2, cetuximab for colorectal cancer,
gefetinib and erlotinib as a second-line treatment for non-small cell
lung cancer (Hynes and Lane, 2005; Johnston et al, 2006).
An emerging theme in the clinical application of ERBB inhibitors
is the combined use with other drugs, such as chemotherapy,
mammalian target of rapamycin inhibitor, anti-oestrogen agents or
vascular endothelial growth factor receptor inhibitor (Hynes and
Lane, 2005). Owing to the possibility of organ-specific functions of
EGF signalling in promoting metastasis, clinical trials should
measure both generalised and organ-specific outcome of metastasis.
MECHANISMS OF BONE HOMOEOSTASIS AND
METASTASIS
Bone metastasis is the major cause of morbidity of several
carcinomas. In one study involving 4399 patients, bone metastasis
inflicts on 48% of breast cancer patients, 90% of prostate cancer
patients, 39% of lung cancer patients and 35% of kidney cancer
patients (Hess et al, 2006; Lu and Kang, 2007). It was estimated
that 350000 cancer patients die each year with bone metastasis
(Mundy, 2002). Bone metastasis is often associated with bone pain,
fracture, hypercalcemia, nerve compression syndromes, leukoer-
ythroblastic anaemia and paralysis (Mundy, 2002; Roodman, 2004;
Guise, 2009). Bone metastasis is classified as either osteolytic or
osteoblastic, which actually represent two extremes of a continual
spectrum of metastasis-associated bone pathology. Even though
most bone metastases contain both osteolytic and osteoblastic
components, metastases from breast and lung cancer usually are
predominantly osteolytic, whereas metastases from prostate cancer
are predominantly osteoblastic (Mundy, 2002). Bone lesion caused
by myeloma is purely osteolytic.
Important insights of bone metastasis have been gained from a
better molecular understanding of normal bone homoeostasis. The
adult skeleton is constantly under coordinated remodelling that is
mediated by a balanced activity of osteoblasts and osteoclasts
(Mundy, 2002; Roodman, 2004; Guise, 2009). Osteoclast activation
requires two cytokines, macrophage colony stimulating factor and
receptor activator of nuclear factor-kB ligand (RANKL), both of
which are expressed by osteoblasts and stromal cells. The RANKL
activity is antagonised by a soluble decoy receptor osteoprotegerin
(OPG), which is also expressed by osteoblasts and stromal cells.
Local RANKL/OPG ratio determines the osteoclastogenic potential.
Binding of RANKL to RANK expressed on osteoclast precursors
activates nuclear factor-kB and Jun N-terminal kinase pathways
to induce differentiation (Boyle et al, 2003). Therefore, most
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and 1,25-dihydroxyvitamin D, stimulate osteoclast differentiation
by indirectly signalling through osteoblasts and stromal cells to
increase RANKL expression or to decrease OPG expression.
Osteoblasts are derived from mesenchymal stem cells. Runx-2 is
the essential transcription factor orchestrating the differentiation
programme in osteoblast precursors (Harada and Rodan, 2003).
Cytokines inducing osteoblast differentiation include bone
morphogenetic proteins (BMPs), platelet-derived growth factor,
fibroblast growth factors and TGF-b.
In multiple myeloma, osteoclastogenic factors, such as inter-
leukin-6, RANKL and macrophage inflammatory protein 1a, are
abundantly expressed by myeloma cells (Roodman, 2004). Mean-
while, myeloma cells also express dickkopf 1, an inhibitor of
osteoblast differentiation (Tian et al, 2003). These two mechanisms
together can explain the purely osteolytic nature of bone lesions
formed by myeloma. The osteolytic activity of breast cancer bone
metastasis is partially because of the high expression level of PTH-
related protein (PTHrP) in bone-metastatic tumour cells. The
percentages of PTHrP-positive tumours in primary site, metastases
in bone and metastases in other sites were 60, 92 and 17%,
respectively (Powell et al, 1991). The PTHrP, together with other
tumour-secreted factors, such as interleukin-1, interleukin-6 and
interleukin-11, stimulates RANKL production or decreases OPG
expression in osteoblasts and stromal cells. Elevated RANKL/OPG
ratio favours osteoclast activation and bone resorption. Bone-
released growth factors (e.g. insulin-like growth factor1 (IGF1),
TGF-b) and calcium cause more PTHrP production and prolifera-
tion of tumour cells. The so-called ‘vicious cycle’ has the central
role in the osteolysis and tumour growth of breast cancer
metastasis to bone (Figure 1). Different set of molecules account
for the osteoblastic nature of prostate metastasis to bone. Prostate
cancer cells express osteoblastic factors, including endothelin-1,
platelet-derived growth factor, TGF-b2, BMPs, urokinase
plasminogen activator (uPA), fibroblast growth factors 1 and 2,
which are all associated with proliferation of osteoblasts (Figure 1)
(Mundy, 2002; Roodman, 2004). Osteoblastic metastases may be
preceded by osteoclast activation and bone destruction, raising the
possibility of targeting bone resorption in the treatment of bone
metastasis of prostate cancer (Roodman, 2004). Currently, most
drugs specifically targeting bone metastasis are inhibitors of bone
resorption. Bisphosphanate blocks bone resorption by targeting
osteoclasts and has been approved for the treatment of skeletal
complications of malignancy. Bone metastasis drugs in clinical
trials include OPG, RANK-Fc, PTHrP antibody and vitamin D
analogues (Mundy, 2002). Clearly, identification of new molecules
involved in osteolytic bone metastasis will provide new thera-
peutics possibilities.
EGF SIGNALLING IN BONE DEVELOPMENT
The balance between osteoblasts and osteoclasts can be perturbed by
altering the activity of EGF signalling. Early in vitro studies showed
that addition of TGF-a and EGF to bone marrow culture, foetal rat
long bone and neonatal mouse calvaria stimulated osteoclast
formation and bone resorption (Ibbotson et al,1 9 8 6 ;L o r e n z o
et al, 1986; Takahashi et al, 1986). Phenotypes from genetically
modified mice confirmed the important role of EGF signalling in
bone formation. In both newborn EGFR-null mice (Wang et al, 2004)
and 4-week-old AREG-null mice (Qin et al, 2005), trabecular bone
area was decreased compared with wild-type mice, indicating the
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Figure 1 Multifunctional role of epidermal growth factor (EGF) signalling in bone development and metastasis. (A) In healthy bone, a proper level of
osteoclast differentiation is ensured by a balance of receptor activator of nuclear factor-kB ligand (RANKL) and osteoprotegerin (OPG) expression by
osteoblasts and stromal cells. (B) During bone development, EGF-like ligands secreted by bone cells promotes the proliferation of osteoblast progenitors.
(C) The EGF-like ligands secreted by bone cells inhibit differentiation of osteoblast progenitors. (D) Osteolytic tumour cells (e.g. breast cancer) express
cytokines that regulate the expression of RANKL or OPG in osteoblasts, and ultimately activate osteoclasts and bone resorption. (E) Bone resorption
releases growth factors and Ca
2þ to promote tumour growth and more bone osteolysis. Continuous processes of D and E constitute the ‘vicious cycle’. (F)
Osteoblastic tumour cells (e.g. prostate cancer) secret cytokines that activate osteoblast proliferation. (G) Overexpression of metalloproteinases, such as
matrix metalloproteinase 1 (MMP1) and a disintegrin-like and metalloprotease with thrombospondin 1 (ADAMTS1), in metastatic tumour cells mediate
ectodomain shedding of EGF-like ligands. (H) The soluble EGF-like ligands can promote tumour cell proliferation through an autocrine loop. (I) The soluble
EGF-like ligands inhibit OPG expression from osteoblasts and tip the RANKL/OPG balance towards osteoclastogenesis. Whether EGF-like ligands from
tumour cells can influence osteoblast progenitor proliferation (B) and differentiation (C) is unknown. CTGF, connective tissue growth factor.
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primary endochondral ossification during embryonic development
due to impaired osteoclast recruitment (Wang et al,2 0 0 4 ) .G e n e t i c
evidence also suggested the involvement of EGFR in the regulation of
osteoblasts. In hEGFR
KI knock-in mice, in which the human EGFR
cDNA was used to replace the mouse Egfr gene, hypomorphic
expression of hEGFR in the knock-in animals reduces the
proliferation and increases the differentiation of primary calvarial
osteoblasts (Sibilia et al,2 0 0 3 ) .I nE G Ft r a n s g e n i cm i c e ,a b n o r m a l
accumulation of osteoblasts in the periosteum and endosteum was
observed (Chan and Wong, 2000). Furthermore, growth retardation
was observed in hEGFR
KI/KI mice (Sibilia et al, 2003) and EGF/
AREG/TGF-a triple-knockout mice (Kelly et al, 2001), possibly due
to impaired longitudinal growth of long bones (Sibilia et al, 2003).
Curiously, slower growth was also observed in EGF transgenic mice,
possibly through a different mechanism involving reduced level of
serum insulin-like growth factor-binding protein-3 (Chan and Wong,
2000). The EGFR is shown to be expressed in osteoblasts but not in
osteoclasts (Zhu et al, 2007). Taking the mouse phenotype and
expression data together, the main function of EGF signalling in
balancing osteoblast/osteoclast activities seems to stimulate the
proliferation of preosteoblasts while inhibiting their full differentia-
tion (Figure 1). By doing this, EGF signalling can indirectly influence
osteoclast number and activity. The indirect role of EGF signalling in
osteoclastogenesis was explored using either the mesenchymal stem
cell-like cells (Normanno et al, 2005) or osteoblast cell lines (Zhu
et al, 2007; Lu et al, 2009), and the results suggest that activation of
the signalling pathway upregulates RANKL, macrophage colony
stimulating factor and MCP-1, but downregulates OPG (Figure 1).
The overall consequence of these regulations is enhanced osteoclast
differentiation. This notion has direct implications in osteolytic bone
metastasis growth, because EGF family ligands are frequently
expressed in carcinomas (as discussed above). It is conceivable that
by interacting with osteoblasts through paracrine EGF signalling, the
tumour cells can ultimately promote osteoclastogenesis. Indeed, this
possibility was confirmed in our recent study (Lu et al, 2009).
EGF SIGNALLING IN OSTEOLYTIC BONE METASTASIS
Involvement of EGF signalling in the pathogenesis of bone
metastasis was implicated by the unexpected relief of bone pain
in phase II clinical trials of EGFR inhibitor gefitinib in breast
cancer patients (Albain et al, 2002; von Minckwitz et al, 2005). The
inhibitory effect on tumour growth in bone can be exerted through
two possible mechanisms: by directly blocking tumour cell
proliferation, or by indirectly blocking tumour–stroma signalling
cross talks that are essential for the continuous metastasis
development. Results from a number of studies that evaluated
the therapeutic benefit of targeting EGF signalling in preclinical
bone metastasis models suggest that both mechanisms may be
involved, and sometimes simultaneously. Bone metastasis formed
by ERBB2-overexpressing breast cancer cell, BT474, was signifi-
cantly blocked with trastuzumab, presumably due to reduced
MARK pathway activity in tumour cells (Khalili et al, 2005).
Blocking EGFR phosphorylation with the tyrosine kinase inhibitor,
PKI166, reduced bone metastasis formation and bone destruction
in a renal cell carcinoma model (Weber et al, 2003). Interestingly,
both tumour cells and EGFR-expressing endothelial cells were
induced to undergo apoptosis by the agent, suggesting that
inhibition of angiogenesis may contribute to the efficacy of the
drug. The inhibitory effect of PKI166 on prostate cancer bone
metastasis has also been attributed to the targeting of both tumour
cells and endothelial cells (Kim et al, 2003). In another study on
prostate cancer bone metastasis, gefitinib inhibited the growth of
prostate cancer cell PC3 and its highly bone-metastatic subline
PCb2 at the similar level when cells were grown as subcutaneous
tumours, yet osteolytic bone metastasis was inhibited to a larger
extent in PCb2 (Angelucci et al, 2006). The differential effect on
bone metastasis cannot be readily explained by direct targeting, as
EGFR expression was comparable in two cell lines. Compared with
the parental cell, PCb2 expressed higher level of uPA and
conditioned medium induced more RANKL expression in the
osteoblasts. The enhancement of RANKL expression was blocked
by gefitinib treatment, thus linking the tumour-inhibitory effect of
EGFR inhibitors to RANKL-mediated osteoclast activation.
In one of our recent studies, we showed direct evidence for
reducing bone metastasis growth through inhibiting EGF signal-
ling in bone stromal cells (Lu et al, 2009). In a bone metastasis
model of breast cancer, bone-metastatic variants of the MDA-MB-
231 breast cancer cell line were found to overexpress two
metalloproteinases, MMP1 and ADAMTS1. Ectodomain shedding
by the proteases releases three EGF-like factors, HB-EGF, AREG
and TGF-a, from tumour cells. The soluble factors activates EGFR
pathway in adjacent osteoblasts through a paracrine mechanism
and downregulates OPG expression. The increased ratio of RANKL
and OPG favours osteoclastogenesis and contributes to the vicious
cycle of osteolytic bone metastasis (Figure 1). The EGFR inhibitor-
insensitive MDA-MB-231 cells offered the opportunity to test the
indirect effect of targeting EGFR in bone metastasis. Cetuximab
and gefitinib markedly impeded bone metastasis formation when
the highly bone-metastatic subline of MDA-MB-231 was inoculated
into mice by intracardiac or intratibia injection. Combining two
drugs produced even more significant inhibition. Together, these
results provide a rationale for targeting EGF-like factors (HB-EGF,
AREG and TGF-a) and proteases (MMP1 and ADAMTS1) in
tumour cells, as well as EGFR in osteoblasts for controlling
osteolytic bone metastasis of breast cancer.
CONCLUSION AND FUTURE DIRECTION
The chance of long-term survival for patients with bone metastasis
is usually dismal. For example, only 20% of breast cancer patients
live more than 5 years after the diagnosis of bone metastasis
(Roodman, 2004). Therefore, finding effective therapeutic targets is
urgently needed for controlling this debilitating disease. Studies of
EGF signalling functions in bone development and metastasis
suggest EGF signalling pathway as a promising new target for
controlling osteolytic bone metastasis. It is unknown whether
osteoblastic metastasis can also be reduced by ERBB inhibitors. To
further determine the efficacy and general applicability of the
strategy, testing the therapeutic benefit of EGF signalling inhibi-
tion in additional preclinical models of both osteolytic and
osteoblastic bone metastasis should be performed. One cancer
type that has not been tested but may benefit from ERBB-targeting
therapeutics is myeloma. Both ERBB receptor and ligands are well
documented to be expressed by myeloma cells (Johnston et al,
2006). Finally, clinical trials of using ERBB inhibitors to specifically
reduce bone metastasis and the associated morbidities are needed
to translate recent exciting findings into more effective treatments
for cancer patients with bone metastases.
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